UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

9 Nov 2005

UCB Receives FDA Orphan Drug Designation for Brivaracetam for the Treatment of Symptomatic Myoclonus

Read More
27 Oct 2005

UCB Reports Positive Clinical Trial Results for Keppra® as Adjunctive Therapy in the Treatment of Primary Generalised Tonic-Clonic Seizures

Read More
20 Oct 2005

UCB confirms good performance of Zyrtec in US and Xyzal

Read More
18 Oct 2005

UCB: Phase III study shows CIMZIA(TM) is an effective and well-tolerated treatment for Crohn's disease

Read More
22 Sep 2005

European Commission Approves Use of UCB's Anti-Epileptic Keppra® as Adjunctive Therapy in Children Four Years of Age and Older with Partial-Onset Seizures

Read More
15 Sep 2005

UCB'S ANTI-EPILECTIC KEPPRA® MEETS PRIMARY END-POINT IN MONOTHERAPY TRIAL

Read More

Stay up-to-date on the latest news and information from UCB